What were the key takeaways from Biomarin’s earnings call?

What is the market's earnings forecast for Biomarin next quarter?

What factors drove the changes in Biomarin's revenue and profit?

What guidance did Biomarin's management provide for the next earnings period?

What is Biomarin's gross profit margin?

What is Biomarin's latest dividend and current dividend yield?

Did Biomarin beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Biomarin year over year?

- **Revenue Growth**: 2025 total revenue $3.22 billion (+13% YoY), driven by 26% Voxzogo growth. 
- **Strategic Expansion**: $3.7 billion debt financing for Amicus acquisition, targeting 2030s growth. 
- **Pipeline Momentum**: 
  - BMN 333 Phase II/III to begin Q1 2026, targeting 2.25 cm/year growth. 
  - Voxzogo hypochondroplasia data expected H1 2026. 
- **Financial Strength**: 2026 non-GAAP EPS guidance $4.95-5.15, reflecting $0.25/share Amicus costs. 
- **Market Leadership**: 75% Voxzogo revenue outside U.S., focus on early diagnosis and underpenetrated markets.

**【CEO Summary Section】**
- **2025 Performance Highlights**: Total revenue reached $3.22 billion, up 13% YoY, driven by 9% growth in enzyme therapies and 26% rise in Voxzogo revenue. 
- **Strategic Acquisitions**: 
  - Inoz (BMN 401 for ENPP1 deficiency) and Amicus (Galafold for Fabry, Pombiliti for Pompe) to expand enzyme therapy portfolio. 
  - Amicus acquisition expected to close Q2 2026, with potential for accelerated growth through 2030s. 
- **Pipeline Progress**: 
  - BMN 333 (long-acting CNP) Phase II/III study to begin Q1 2026, targeting 2.25 cm/year growth velocity. 
  - Voxzogo expansion into hypochondroplasia with Phase III data expected H1 2026. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Total revenue $875 million (+17% YoY), with Voxzogo at $287 million (+31% YoY) and enzyme therapies at $588 million (+13% YoY). 
  - Full-year non-GAAP EPS $3.15, up 34% YoY. 
- **2026 Guidance**: 
  - Enzyme therapies: $2.225-2.275 billion (midpoint +7.5%). 
  - Voxzogo: $975-1.025 billion (midpoint +5%). 
  - Total revenue: $3.325-3.425 billion (+3-6% YoY). 
  - Non-GAAP EPS: $4.95-5.15, reflecting $0.25/share pre-close Amicus costs. 
- **Financial Strength**: 
  - Operating cash flow $828 million (+45% YoY). 
  - $3.7 billion debt financing secured for Amicus transaction. 

**【Q&A Key Highlights】**
- **Voxzogo Competition Dynamics**: 
  - 75% of revenue outside U.S., focus on newborns and underpenetrated markets. 
  - Long-term safety/efficacy data (10,000 patient-years) positions Voxzogo against competitors. 
- **BMN 333 Strategy**: 
  - Powered to detect 2.25 cm/year growth vs. placebo, targeting best-in-class status. 
  - Phase III enrollment expected H1 2026. 
- **Amicus Integration**: 
  - Galafold and Pombiliti to fit into enzyme therapy BU, leveraging existing infrastructure. 
  - Focus on undiagnosed patient identification for Fabry/Pompe. 
- **Pipeline Updates**: 
  - Palynziq adolescent label expansion (PDUFA Feb 28, 2026). 
  - BMN 351 Duchenne data at MDA meeting (March 2026).

BioMarin Pharmaceutical Inc.(BMRN)-20260224-2025 Q4 Earnings call transcript

- **Revenue Growth**: 11% YTD increase, driven by Enzyme Therapies (+8%) and VOXZOGO (+24%).
- **Strategic Shift**: Divesting ROCTAVIAN to focus on high-growth Skeletal Conditions and Enzyme Therapies.
- **Financial Strength**: $728M operating cash flow YTD, $2B cash balance, and 26-27% non-GAAP margin guidance.
- **Pipeline Momentum**: BMN 333 Phase II/III for DMD, hypochondroplasia data H1 2026, and global VOXZOGO expansion.

**【CEO Summary Section】**
- Q3 2025 revenue growth of 11% year-over-year, driven by Enzyme Therapies and VOXZOGO in Skeletal Conditions.
- Raised full year total revenue guidance midpoint to $3.15 billion, reaffirming VOXZOGO revenue outlook of $900-935 million.
- Announced divestment of ROCTAVIAN to focus on core business units.
- Highlighted expanding profitability and $2 billion cash balance, with focus on business development opportunities.

**【CFO Financial Commentary】**
- GAAP net income of $420 million; Non-GAAP EPS of $1.08, exceeding expectations.
- Year-to-date operating cash flow of $728 million, supporting strategic investments.
- Updated 2025 non-GAAP operating margin guidance to 26-27%, with EPS guidance of $3.50-3.60.
- Noted $221 million IPR&D charge from Inozyme acquisition impacting Q3 margins.

**【Q&A Key Highlights】**
- **2027 Revenue Scenarios**: Lower case estimate aligns with current FactSet consensus ($3.65 billion excluding ROCTAVIAN), higher case reflects delayed competition ($4 billion+). 
- **VOXZOGO Competition**: Acknowledged potential share loss from 2 competitors, but emphasized strong adherence rates and ex-U.S. growth.
- **Pipeline Updates**: BMN 333 Phase II/III study targeting 10% dystrophin increase; hypochondroplasia Phase III data expected H1 2026.
- **Capital Allocation**: Prioritizing business development over share buybacks, with $4-5 billion firepower for asset acquisitions.

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 16% YoY, full year guidance raised to $3.125 billion.
- **Pipeline Breakthroughs**: BMN 333 shows >3x CNP AUC vs. competitor, Phase II/III study to start H1 2026.
- **Strategic Acquisitions**: Inozyme acquisition adds BMN 401 for ENPP1 deficiency, with pivotal data in H1 2026.
- **Profitability**: Non-GAAP EPS up 3x revenue growth rate, operating margin guidance raised to 33-34%.
- **Key Product Updates**: VOXZOGO U.S. patient starts double YoY, PALYNZIQ adolescent label expansion submissions planned.

**【CEO Summary Section】**
- Q2 2025 revenue grew 16% YoY, driven by global demand and new patient starts across the portfolio.
- Full year 2025 revenue guidance raised to $3.125 billion, reflecting double-digit growth.
- Inozyme acquisition completed in July 2025, expanding enzyme therapies portfolio with BMN 401 for ENPP1 deficiency.
- Pipeline advancements include BMN 333 (long-acting CNP for achondroplasia) and BMN 401 pivotal data readout expected in H1 2026.

**【CFO Financial Commentary】**
- Non-GAAP EPS of $1.44 in Q2, up 3x the revenue growth rate, reflecting strong operating margin expansion.
- Full year 2025 non-GAAP operating margin guidance raised to 33-34%, driven by cost control and revenue growth.
- VOXZOGO revenue expected to reach $900-935 million in 2025, with 25% YoY growth at the midpoint.
- Enzyme Therapies revenue up 15% YoY, led by PALYNZIQ and VIMIZIM growth.

**【Commercial Update (Cristin Hubbard)】**
- VOXZOGO U.S. patient starts doubled YoY, with Q2 revenue up 20% YoY to $221 million.
- Hypochondroplasia Phase III trial enrollment ahead of expectations, targeting 2027 launch.
- PALYNZIQ adolescent label expansion submissions planned for H2 2025, with data readout in H2 2025.
- VIMIZIM revenue up 21% YoY, benefiting from global demand and order timing.

**【R&D Update (Greg Friberg)】**
- BMN 333 Phase I healthy volunteer study shows free CNP levels >3x AUC of competitor, supporting best-in-class potential.
- BMN 333 Phase II/III registrational study to begin H1 2026, targeting 2030 approval.
- BMN 401 pivotal data readout expected in H1 2026 for ENPP1 deficiency, with 2,000-2,500 addressable patients globally.
- PALYNZIQ adolescent study data submission planned for H2 2025, targeting 2026 approvals.

**【Q&A Highlights】**
- BMN 333 Phase III trial design: 3x AUC target vs. VOXZOGO, with safety profile supported by preclinical and genetic data.
- VOXZOGO discontinuation rates remain low (~5%), driven by patient support programs.
- 2027 $4 billion revenue target update expected by year-end, incorporating Inozyme acquisition and pipeline progress.
- ITC proceedings timeline: initial determination June 2026, final investigation completion October 2026.
- ENPP1 deficiency prevalence estimate 2,000-2,500 patients globally, with Inozyme identifying >600 patients pre-acquisition.

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

- **15% Revenue Growth**: Q1 2025 revenue $745M, driven by 40% YoY VOXZOGO and 8% Enzyme Therapies growth.
- **Profitability Leap**: Non-GAAP EPS $1.13 (+59% YoY), operating margin 35.7% (up 11.9ppt).
- **Pipeline Momentum**: Phase 3 hypochondroplasia data for VOXZOGO; PALYNZIQ adolescent submissions in 2025.
- **Cash Generation**: $174M operating cash flow, up 271% YoY, fueling innovation.
- **Tariff Resilience**: 67% ex-US revenue, US-based manufacturing for rare disease drugs.

**【CEO Summary Section】**
- Q1 2025 revenue grew 15% YoY to $745M, driven by VOXZOGO (40% YoY) and Enzyme Therapies (8% YoY). Non-GAAP EPS of $1.13 rose 59% YoY.
- Strategic transformation since Sep 2024 has improved profitability, with operating margin expanding 11.9ppt to 35.7%.
- Protected against pharmaceutical tariffs via global revenue mix (67% ex-US) and manufacturing (US-based for rare disease drugs).
- Pipeline progress: Phase 3 hypochondroplasia study for VOXZOGO completed enrollment; PALYNZIQ adolescent data supports 2025 EU/US submissions.

**【CFO Financial Commentary】**
- VOXZOGO global revenue $214M (40% YoY), Enzyme Therapies $484M (8% YoY). PALYNZIQ up 22% YoY, ALDURAZYME +40% YoY.
- Non-GAAP R&D expense $147M (down YoY), SG&A $183M (down YoY) due to cost transformation. Full year 2025 R&D and SG&A to increase for pipeline investments.
- Operating cash flow $174M (271% YoY growth), supporting innovation and growth.

**【Commercial Update】**
- VOXZOGO available in 49 countries, targeting >60 by 2027. US patient uptake initiatives include expanded field teams and guideline-aligned early treatment.
- Enzyme Therapies: PALYNZIQ adolescent data shows Phe control benefits; VIMIZIM order dynamics typical for mature brands.

**【R&D Progress】**
- VOXZOGO hypochondroplasia Phase 3 data expected 2026, targeting 2027 launch.
- BMN 333 (long-acting CNP) Phase 1 PK data in H2 2025; FDA agreement on pivotal plan for 2030 approval.
- BMN 351 (Duchenne) 25-week dystrophin data in H2 2025; modeling predicts 10%+ steady-state levels.

**【Q&A Highlights】**
- VOXZOGO H2 2025 revenue growth expected despite Q2 flattish trends due to order timing.
- Tariff exposure immaterial; mitigation strategies include global supply chain and IP rights.
- Business development focus on rare disease assets; 1+ deals expected in 2025.
- BMN 333 pivotal study to compare efficacy vs VOXZOGO, targeting superior outcomes.
- VOXZOGO manufacturing exclusively US-based for rare disease drugs.

BioMarin Pharmaceutical (BMRN)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 full-year revenue up 18% to $2.85B, with 2025 guidance of $3.1-3.2B (+10%).
- **VOXZOGO Dominance**: 56% YoY growth, targeting $900-950M in 2025. 76% of Q4 revenue from ex-US, with 2027 global access in >60 countries.
- **Profitability Expansion**: Non-GAAP operating margin 28.6% in 2024, targeting 40% by 2027. 2025 EPS guidance $4.20-4.40, +2x top-line growth rate.
- **Pipeline Momentum**: BMN 351 DMD Phase I/II data H2 2025; PALYNZIQ adolescent expansion filing expected H2 2025.
- **Cost Efficiency**: $500M cost savings achieved, driving operating cash flow to $573M in 2024 (+260% YoY).


**【CEO Summary Section】**
- **Record Financial Performance**: 2024 full-year revenue grew 18% to $2.85 billion, with non-GAAP EPS increasing 69% to $3.52. The company is on track for double-digit revenue growth in 2025.
- **VOXZOGO Dominance**: Skeletal conditions leader with VOXZOGO revenue up 56% YoY, driven by global expansion (76% of Q4 revenue from ex-US). 2025 target: $900-950 million from VOXZOGO.
- **Pipeline Momentum**: BMN 351 (Duchenne muscular dystrophy) Phase I/II data expected H2 2025; BMN 333 (long-acting CNP) PK study results anticipated late 2025. PALYNZIQ Phase III for adolescents to read out mid-2025.
- **Cost Transformation**: Achieved $500 million cost savings, driving non-GAAP operating margin to 28.6% in 2024 (up 920bps YoY). Target 40% margin by 2027.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q4 2024 revenue $747 million (+16% YoY), with VOXZOGO contributing $208 million. Full-year enzyme therapy revenue $1.9 billion (+12% YoY).
- **Profitability Expansion**: Non-GAAP operating margin 31.1% in Q4, up from 24.3% YoY. Full-year non-GAAP EPS $3.52, up 69% YoY.
- **2025 Outlook**: Total revenue $3.1-3.2 billion (+10% YoY). Non-GAAP operating margin 32-33%, up 390bps YoY. EPS $4.20-4.40, +2x top-line growth rate.
- **Cash Flow**: Full-year operating cash flow $573 million (+260% YoY), targeting $1.25 billion by 2027.

**【Commercial Highlights】**
- **VOXZOGO Global Leadership**: 47% of U.S. prescribers are pediatric endocrinologists; 74% of Q4 revenue from ex-US. 2027 target: >60 countries with access.
- **Enzyme Therapy Resilience**: PALYNZIQ +17% YoY growth; NAGLAZYME and ALDURAZYME growth driven by new patient starts and order timing.
- **Pipeline Expansion**: CANOPY Phase III for hypochondroplasia on track for 2026 data; BMN 349 (AATD) Phase I healthy volunteer study ongoing.

**【Q&A Key Takeaways】**
- **VOXZOGO Growth Drivers**: U.S. expansion (25% of 2024 revenue), ex-US penetration (76% Q4), and 2027 hypochondroplasia launch. 2025 growth to be weighted to H2.
- **Business Development Strategy**: Focused on genetically defined conditions; 155 JPMorgan meetings highlight global commercialization appeal.
- **BMN 351 DMD Risk**: 10% dystrophin target at 6mg/kg; 25-week biopsy data H2 2025 will guide future dosing.
- **Competitive Landscape**: VOXZOGO's 6,000+ patient-year safety profile and global infrastructure provide switching resistance.


BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

BioMarin Pharmaceutical (BMRN)-29 Oct 24-2024 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-5 Aug 24-2024 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-24 Apr 24-2024 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-22 Feb 24-2023 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-1 Nov 23-2023 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-31 Jul 23-2023 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Apr 23-2023 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-28 Feb 23-2022 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-27 Oct 22-2022 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-4 Aug 22-2022 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-28 Apr 22-2022 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-24 Feb 22-2021 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-28 Oct 21-2021 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-29 Jul 21-2021 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-30 Apr 21-2021 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Feb 21-2020 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-7 Nov 20-2020 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-4 Aug 20-2020 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-30 Apr 20-2020 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Feb 20-2019 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-23 Oct 19-2019 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-2 Aug 19-2019 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-27 Apr 19-2019 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-22 Feb 19-2018 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Oct 18-2018 Q3 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-3 Aug 18-2018 Q2 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Apr 18-2018 Q1 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-23 Feb 18-2017 Q4 Earnings call transcript

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN)-26 Oct 17-2017 Q3 Earnings call transcript

Actual											0.44	-0.16	4.01	0.12	0.09	0.07	-0.2	-0.32	0.63	0.15	-0.04	0	0.27	0.29	0.21	0.11	0.46	0.55	0.55	0.64	0.95	1.23	-0.16	-0.24
Forecast											0.0311	-0.1126	0.25	-0.1681	-0.0892	-0.1091	-0.2501	-0.3625	0.2125	0.0329	-0.012	-0.0583	0.1551	0.2114	0.2195	0.1972	0.3118	0.3578	0.531	0.534	0.7141	0.8608	-0.2801	0.1694
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1314.79%	-42.10%	+1504.00%	+171.39%	+200.90%	+164.16%	+20.03%	+11.72%	+196.47%	+355.93%	-233.33%	+100.00%	+74.08%	+37.18%	-4.33%	-44.22%	+47.53%	+53.72%	+3.58%	+19.85%	+33.03%	+42.89%	+42.88%	-241.68%

BMRN

BMRN fundamentals

BMRN Q4 2025 Earnings

Earnings Call

You can ask Aime

BMRN

BMRN fundamentals

BMRN Q4 2025 Earnings

Earnings Call

BMRN Earnings Call Summary for Q4/20254:30 PM on Feb 23, 2026

BMRN Earnings Call Summary for Q3/20254:30 PM on Oct 27, 2025

BMRN Earnings Call Summary for Q2/20254:30 PM on Aug 4, 2025

BMRN Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

BMRN Earnings Call Summary for Q4/20244:30 PM on Feb 19, 2025

You can ask Aime